Evexia Lifecare Q2 Results: Profit Falls 38% in FY27

Quarterly results approved by the board

Evexia Lifecare Ltd's board approved the unaudited standalone and consolidated financial results for the quarter ended September 30, 2026, at its meeting on October 24, 2026. The company also considered the limited review reports issued by statutory auditor Tejas K. Soni & Company. The filing showed a decline in consolidated revenue and profit from the corresponding quarter of the previous year. It also contained significant audit observations relating to credit-risk assessment, investments and supporting documentation.

Consolidated profit declines year on year

On a consolidated basis, net profit for Q2 FY27 was ₹0.23 crore, compared with ₹0.37 crore in Q2 FY26. This represents a year-on-year decline of 37.89%. Profit before tax fell 28.19% to ₹0.37 crore from ₹0.51 crore a year earlier. Basic and diluted earnings per share were ₹0.001, against ₹0.002 in the comparable quarter.

A separate disclosure in the filing stated that net profit attributable to owners was ₹0.28 crore in Q2 FY27, compared with ₹0.37 crore in Q2 FY26. The reported consolidated net-profit figure of ₹0.23 crore remains the figure presented in the quarterly results summary. Investors may need to refer to the complete financial statements and notes for the reconciliation of these disclosures.

Revenue slips to ₹25.02 crore

Consolidated revenue from operations stood at ₹25.02 crore in the September 2026 quarter, down 2.75% from ₹25.73 crore in the year-ago period. Total income declined 1.32% to ₹25.82 crore from ₹26.16 crore. On a sequential basis, the supplied financial data showed sales of ₹25.0 crore in September 2026, compared with ₹30.9 crore in June 2026.

The company reported an operating loss of about ₹0.1 crore for the quarter, compared with an operating profit of ₹0.1 crore in September 2025. Other income rose to ₹0.8 crore from ₹0.4 crore a year earlier. The available filing analysis indicated that pre-tax profit was supported by other income or one-off items rather than operating profit.

Standalone profit rises despite lower income

Standalone net profit was ₹0.38 crore for Q2 FY27, up 20.94% from ₹0.32 crore in Q2 FY26. Standalone revenue from operations was ₹23.83 crore, down from ₹25.03 crore in the year-earlier quarter. Total standalone income was ₹24.63 crore, compared with ₹25.37 crore.

Standalone profit before tax increased to ₹0.52 crore from ₹0.43 crore. The contrast between higher standalone profit and lower consolidated profit reflects the different performance and accounting effects included in the two sets of results. The company has not provided a separate detailed operational explanation in the information supplied.

Key financial figures

Auditor cites missing ECL assessments

The statutory auditor issued a disclaimer of conclusion in the limited review report. The auditor said it could not obtain sufficient appropriate evidence regarding significant credit-risk exposures and potential material misstatements. A central observation was the absence of expected credit loss, or ECL, assessments for loans receivable of ₹7.35 crore and trade receivables of ₹29.44 crore.

Management has considered these balances recoverable. However, the auditor said it was unable to comment on their recoverability or on any provision that may be required because sufficient evidence was not available. ECL assessment is important because it determines whether a company needs to recognise a provision against amounts that may not be collected.

Other observations in the review report

The audit observations also covered an unlisted equity investment of ₹0.87 crore for which fair value had not been determined. The report referred to deficiencies in provisions and the availability of documentation. These matters form part of the auditor's basis for being unable to provide a conclusion on the financial statements under review.

The filing also referred to an investment and loan exposure of ₹1.28 crore in Kavit Edible Oil Limited. Its production has reportedly remained shut since March 2019, while its net worth was negative as of March 2026. The auditor noted doubt over that entity's ability to continue as a going concern.

Subsidiary information and compliance matters

The consolidated results include unaudited interim financial information for six subsidiaries that was not reviewed by their auditors. The results of Vital's Healthcare Private Limited and its associate, as well as Heemsol Energy Solutions Private Limited, were not included in the consolidated results, according to the provided filing summary. Management said no material adjustments were required for tax disputes and statutory-compliance matters based on legal advice.

These disclosures are relevant because consolidated accounts depend on information received from subsidiaries and other entities within the group. The filing does not quantify the possible financial effect, if any, of the excluded entities or audit observations. Therefore, the disclosures should be read along with the detailed notes to the results and review reports.

Cash flow remains under pressure

The consolidated cash flow statement recorded a net decrease of ₹1.08 crore in cash and cash equivalents during the half year ended September 30, 2026. The supplied analysis also stated that operating cash flow was negative in FY26 and remained negative in the first half of FY27 despite the company reporting profit. Cash-flow trends are relevant because accounting profit and cash generated from operations can differ materially.

The quarterly operating performance was also weak on the available data, with an operating loss in Q2 FY27. While other income increased, it did not change the reported decline in consolidated net profit. The financial results therefore place focus on working-capital recoverability, operating cash generation and the resolution of audit observations.

FCCB conversion expands share capital

During the quarter, Evexia Lifecare allotted 34.07 crore equity shares at a premium of ₹0.40 per share after the conversion of 50 Foreign Currency Convertible Bonds. Following the allotment, paid-up equity share capital rose to ₹221.80 crore as of September 30, 2026, from ₹187.73 crore as of March 31, 2026. The increase in outstanding equity capital is relevant to per-share metrics and shareholder dilution.

The company reported basic and diluted EPS of ₹0.001 for the quarter. With the capital base having expanded following the FCCB conversion, investors assessing per-share performance will need to consider the changed number of shares in issue.

What the Q2 filing means

The Q2 FY27 filing combines lower consolidated revenue, a sharp decline in consolidated profit and material limitations identified in the audit review. The higher standalone profit does not alter the consolidated decline or the auditor's stated inability to obtain sufficient evidence on specified balances. The board has taken the unaudited results and limited review reports on record, while the filing leaves the highlighted ECL, valuation and documentation matters open for management assessment.

The next set of company disclosures, including subsequent quarterly financial statements and any updates on receivable assessment, may provide further clarity on these issues.